• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Clovis Oncology Inc. (Amendment)

    2/11/22 8:18:06 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVS alert in real time by email
    SC 13G/A 1 p22-0850sc13ga.htm CLOVIS ONCOLOGY, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 3)*
     

    Clovis Oncology, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    189464100

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 18946410013G/APage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    11,056,229 shares of Common Stock issuable upon conversion of convertible notes

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    11,056,229 shares of Common Stock issuable upon conversion of convertible notes

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,056,229 shares of Common Stock issuable upon conversion of convertible notes

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.84%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 18946410013G/APage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Clovis Oncology, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301.

     

    Item 2(a). NAME OF PERSON FILING:
      This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of Common Stock (as defined in Item 2(d) below) and the shares of Common Stock issuable upon conversion of certain convertible notes directly held by the Highbridge Funds.
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:
       
      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      189464100

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,

     

    CUSIP No. 18946410013G/APage 4 of 6 Pages

     

      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:    

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 129,979,097 shares of Common Stock outstanding as of October 29, 2021, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 3, 2021 and assumes the conversion of the convertible notes reported herein.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. 

     

    CUSIP No. 18946410013G/APage 5 of 6 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 18946410013G/APage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 11, 2022

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

    Get the next $CLVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVS

    DatePrice TargetRatingAnalyst
    5/6/2022Buy → Neutral
    H.C. Wainwright
    9/21/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    8/5/2021$12.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLVS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Clovis Oncology Inc.

      EFFECT - Clovis Oncology, Inc. (0001466301) (Filer)

      7/18/23 12:15:24 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Clovis Oncology Inc.

      15-12G - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:09:55 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clovis Oncology Inc.

      S-8 POS - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:05:29 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

      Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today. "I am very pleased to welcome Dr. Ronit Simantov to the Clovis Oncology Board of Directors, as she brings a wealth of expertise in oncology research and drug development to the role," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Dr. Simantov's extensive background and experience will support Clovis' key strategic priorities as we continue to advance both Rubraca's pipeline into a potentially broader label and the Company's early-stage pipeline of targeted radiotherapy candidates, including FAP-2286, into clinical development." Dr. Simanto

      7/12/21 4:05:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clovis Oncology Inc. (Amendment)

      SC 13G/A - Clovis Oncology, Inc. (0001466301) (Subject)

      2/10/23 9:48:18 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Clovis Oncology Inc.

      SC 13G - Clovis Oncology, Inc. (0001466301) (Subject)

      7/8/22 4:56:55 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clovis Oncology Inc. (Amendment)

      SC 13G/A - Clovis Oncology, Inc. (0001466301) (Subject)

      4/11/22 1:58:59 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clovis Oncology downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Clovis Oncology from Buy to Neutral

      5/6/22 11:33:29 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      9/21/21 6:26:42 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      8/5/21 6:07:39 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

      Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the "Debtors") have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell their assets through a court supervised sales process. The Debtors have filed various "first day" motions with the Bankruptcy Court request

      12/12/22 12:18:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

      Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, "TRITON3: A Phase 3 Study of Rucaparib vs. Physician's Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)" is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, "Novel Clinical Trial Updates" at the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat. The presentation is available at https

      10/27/22 5:05:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

      Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose No serious adverse events, treatment discontinuations, or deaths related to 177Lu-FAP-2286 observed Confirmed partial response (PR) in one patient who completed the maximum six administrations of 177Lu-FAP-2286 in the 3.7 GBq dose cohort Patient continues without disease progression or subsequent anti-cancer therapy more than twelve months after first dose Stable disease (SD) in one heavily pretreated patient who completed four administrations of 177Lu-FAP-2286 in the 5.55 GBq dose coho

      10/17/22 3:45:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      12/22/22 4:37:40 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      6/13/22 2:20:18 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Financials

    Live finance-specific insights

    See more
    • Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

      First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowest (3.7 GBq) dose cohort Recruitment of third of four planned dose cohorts is ongoing Initiation of Phase 2 expansion cohorts in multiple tumor types anticipated in Q4 2022 Phase 3 ATHENA trial evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in front-line maintenance treatment of ovarian cancer presented at 2022 ASCO Annual Meeting Simultaneous publication in the Journal of Clinical Oncology (JCO) Presented at

      8/8/22 8:00:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

      Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days. Dial-in numbers for the conference call are as follows: US participants 888.440.4615 International participants 646.

      7/20/22 4:00:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

      ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in ITT population Late-breaker data to be presented in oral session at 2022 ASCO Annual Meeting on Monday, June 6 Two additional top-line Phase 3 data read-outs for Rubraca expected in next 12 months with potential to address ovarian and prostate cancer patient populations Initial Phase 1 clinical data for targeted radiothera

      5/4/22 8:00:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Rolfe Lindsey converted options into 8,374 shares and sold $4,188 worth of shares (4,261 units at $0.98), increasing direct ownership by 4% to 113,691 units (tax withholding)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:14 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gross Paul Edward converted options into 10,248 shares and sold $4,649 worth of shares (4,730 units at $0.98), increasing direct ownership by 6% to 98,330 units (for tax liability)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:43 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ivers-Read Gillian C converted options into 8,374 shares and sold $3,618 worth of shares (3,681 units at $0.98), increasing direct ownership by 2% to 293,612 units to satisfy withholding obligation

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:37 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care